Cancer-Treatment-Induced Bone Loss, Part 2

Laura Boehnke Michaud; Susan Goodin


Am J Health Syst Pharm. 2006;63(6):534-546. 

In This Article


Early identification and treatment of CTIBL are essential to prevent fractures. Patients should be instructed to optimize calcium and vitamin D intake, participate in a regular exercise program, and modify lifestyle behaviors known to cause bone loss. Patients with CTIBL should be treated with an oral or i.v. bisphosphonate; a SERM or HRT may be an option for some patients if contraindications do not exist. Because the most effective drug, dose, and regimen for the treatment of CTIBL are unknown, therapy should be individualized.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: